Drug lag and key regulatory barriers in the emerging markets
There have been numerous investigations targeted at identifying whether a drug lag exists in the mature markets of the US, EU and Japan. This work focuses on the emerging markets because of the potential they hold for the future of the pharmaceutical industry as a consequence of rapid economic and p...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2010-01-01
|
| Series: | Perspectives in Clinical Research |
| Subjects: | |
| Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2010;volume=1;issue=2;spage=51;epage=56;aulast=Wileman |
| _version_ | 1819017168719708160 |
|---|---|
| author | Harriet Wileman Arun Mishra |
| author_facet | Harriet Wileman Arun Mishra |
| author_sort | Harriet Wileman |
| collection | DOAJ |
| description | There have been numerous investigations targeted at identifying whether a drug lag exists in the mature markets of the US, EU and Japan. This work focuses on the emerging markets because of the potential they hold for the future of the pharmaceutical industry as a consequence of rapid economic and political development.
The aims of this work are to ascertain whether a drug lag exists in the emerging markets and how it has changed over time from the 1960s to the 2000s. It will also highlight key regulatory barriers which may contribute to drug lag.
The date of the marketing authorisation (MA) approval by the US Food and Drug Administration (FDA) was used as a reference point. A comparison against the company database regarding emerging market specific approval enabled the difference in time and thus the drug lag for that particular market to be calculated.
This work concludes that the overall relative drug lag in the emerging markets has decreased over time and that there are seven key regulatory barriers which need to be targeted in order to make further improvements; ′Western Approval′, local clinical development (LCD), Certificate of Pharmaceutical Product (CPP), Good Manufacturing Practice (GMP), pricing approval, document authentication and harmonisation. |
| first_indexed | 2024-12-21T02:59:14Z |
| format | Article |
| id | doaj.art-c0e5aa46bd8c4821a9029f9de0aff0fb |
| institution | Directory Open Access Journal |
| issn | 2229-3485 |
| language | English |
| last_indexed | 2024-12-21T02:59:14Z |
| publishDate | 2010-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Perspectives in Clinical Research |
| spelling | doaj.art-c0e5aa46bd8c4821a9029f9de0aff0fb2022-12-21T19:18:14ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852010-01-01125156Drug lag and key regulatory barriers in the emerging marketsHarriet WilemanArun MishraThere have been numerous investigations targeted at identifying whether a drug lag exists in the mature markets of the US, EU and Japan. This work focuses on the emerging markets because of the potential they hold for the future of the pharmaceutical industry as a consequence of rapid economic and political development. The aims of this work are to ascertain whether a drug lag exists in the emerging markets and how it has changed over time from the 1960s to the 2000s. It will also highlight key regulatory barriers which may contribute to drug lag. The date of the marketing authorisation (MA) approval by the US Food and Drug Administration (FDA) was used as a reference point. A comparison against the company database regarding emerging market specific approval enabled the difference in time and thus the drug lag for that particular market to be calculated. This work concludes that the overall relative drug lag in the emerging markets has decreased over time and that there are seven key regulatory barriers which need to be targeted in order to make further improvements; ′Western Approval′, local clinical development (LCD), Certificate of Pharmaceutical Product (CPP), Good Manufacturing Practice (GMP), pricing approval, document authentication and harmonisation.http://www.picronline.org/article.asp?issn=2229-3485;year=2010;volume=1;issue=2;spage=51;epage=56;aulast=WilemanDrug lag; BRIC countries; N-11 countries; Emerging Markets; Marketing authorisation; Regulatory barriers |
| spellingShingle | Harriet Wileman Arun Mishra Drug lag and key regulatory barriers in the emerging markets Perspectives in Clinical Research Drug lag; BRIC countries; N-11 countries; Emerging Markets; Marketing authorisation; Regulatory barriers |
| title | Drug lag and key regulatory barriers in the emerging markets |
| title_full | Drug lag and key regulatory barriers in the emerging markets |
| title_fullStr | Drug lag and key regulatory barriers in the emerging markets |
| title_full_unstemmed | Drug lag and key regulatory barriers in the emerging markets |
| title_short | Drug lag and key regulatory barriers in the emerging markets |
| title_sort | drug lag and key regulatory barriers in the emerging markets |
| topic | Drug lag; BRIC countries; N-11 countries; Emerging Markets; Marketing authorisation; Regulatory barriers |
| url | http://www.picronline.org/article.asp?issn=2229-3485;year=2010;volume=1;issue=2;spage=51;epage=56;aulast=Wileman |
| work_keys_str_mv | AT harrietwileman druglagandkeyregulatorybarriersintheemergingmarkets AT arunmishra druglagandkeyregulatorybarriersintheemergingmarkets |